News release stated:

"BETonMACE2, Resverlogix's planned, Phase 3, cardiovascular outcomes trial of apabetalone, in patients with type 2 diabetes who are taking SGLT2i, is expected to begin next year."

I didn't see "early" in the release - please correct me if I am wrong, although these trial beginning dates are shifting all the time.

It would be nice to see a cash infusion from Zenith to fund the trial - Zenith shareholders may balk - but probably the best possible situation for RVX shareholders.

GLTA

Chicagoest